Scott E. Woodman

30.1k citations

96 papers · 6.1k indexed · 2 hit papers · h-index 35

Impact in

Cell Biology top 0.5%
- Caveolin-1 and cellular processes
Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research

Papers in

Oncology 53
- Cutaneous Melanoma Detection and Management 20
- Cancer Immunotherapy and Biomarkers 19
- CAR-T cell therapy research 15
Ophthalmology 11
- Ocular Oncology and Treatments 11

Co-authors: Michael P. Lisanti Babak Razani Michael A. Davies Philippe G. Frank David Park Jennifer A. Wargo William Schubert Jason Roszik
Journals: Journal of Clinical Oncology (26 papers)Clinical Cancer Research (7 papers)American Journal Of Pathology (5 papers)Cancer Research (4 papers)Annals of Oncology (3 papers)
Partner nations: United States Australia Italy

In The Last Decade

Scott E. Woodman

95 papers receiving 6.0k citations

Hit Papers

align trajectories log scale

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy 2016 · 913 citations

Peers

Countries citing papers authored by Scott E. Woodman

Since Specialization

Citations

This map shows the geographic impact of Scott E. Woodman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott E. Woodman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott E. Woodman more than expected).

Fields of papers citing papers by Scott E. Woodman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott E. Woodman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott E. Woodman. The network helps show where Scott E. Woodman may publish in the future.

Co-authors

The 25 scholars most cited alongside Scott E. Woodman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott E. Woodman Line = papers co-authored together Scott E. Woodman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal Clinical Cancer Research ·Van K. Morris, Suyu Liu, Kangyu Lin, Haifeng Zhu, Seema Prasad, Armeen Mahvash, Priya Bhosale, Baohua Sun, Edwin R. Parra, Ignacio I. Wistuba, 時彦田中, James C. Yao, 李向阳, Mark Knafl, Scott E. Woodman, Cathy Eng, Daniel M. Halperin	2025	1
2	Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. Journal of Clinical Oncology ·Kosuke Adachi, Ramona Dadu, Naifa L. Busaidy, Renata Ferrarotto, Maria Gule-Monroe, Suyu Liu, Bryan Fellman, Michelle D. Williams, Killian Campbell, Jennifer Wang, Charles Lu, Matthew S. Ning, Brian McKinley, Scott E. Woodman, Dzifa Y. Duose, Maria E. Cabanillas, G. Brandon Gunn	2024	3
3	Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma Cancer Research Communications ·Nicholas J. Hornstein, Mohammad A. Zeineddine, Se Ho, Andrew J. Pellatt, Mark Knafl, Haifeng Zhu, Rosanna O'Keeffe, Abdelrahman Yousef, Suyu Liu, Ryan Sun, P. Andrew Futreal, Scott E. Woodman, Melissa W. Taggart, Michael J. Overman, Daniel M. Halperin, Kanwal Raghav, John Paul Shen	2024	3
4	Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy Cancers ·هالة فغرور, Yohei Kuwada, 谢韩涛, Lingzhi Hong, Y Mao, Richard B. Sibson, Shawna M. Hubert, Xiuning Le, Natalie I. Vokes, Kunal Rai, Ara A. Vaporciyan, Don L. Gibbons, John V. Heymach, J. Jack Lee, Scott E. Woodman, Caroline Chung, David A. Jaffray, Mehmet Altan, Yanyan Lou, Jianjun Zhang	2024	1
5	P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer Annals of Oncology ·Van K. Morris, Haifeng Zhu, Xiaoling Li, Benny Johnson, C. Shambu Prasad, Armeen Mahvash, Baohua Sun, Sadanand Gite, R. Panduregan, Edwin R. Parra, Mark Knafl, Scott E. Woodman, Cathy Eng, Daniel M. Halperin	2023	1
6	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 ESMO Open ·Isabella C. Glitza, Michelle Rohlfs, Nandita Guha‐Thakurta, Roland L. Bassett, Chantale Bernatchez, Adi Diab, Scott E. Woodman, Cassian Yee, Rodabe N. Amaria, Sapna P. Patel, Hussein A. Tawbi, Michael K. Wong, Wen-Jen Hwu, Patrick Hwu, Amy B. Heimberger, Ian E. McCutcheon, Nikolaos G. Papadopoulos, Michael A. Davies	2018	47
7	SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity Cancer Immunology Research ·Jungsun Park, Amjad H. Talukder, Seon Ah Lim, Kwanghee Kim, 江浪唐, Brenda Melendez, Sherille D. Bradley, Melva F. Manambing, Jahan S. Khalili, Junmei Wang, Caitlin Creasy, Nadhirotul Uyun, Scott E. Woodman, Chantale Bernatchez, David H. Hawke, Patrick Hwu, Kyung‐Mi Lee, Jason Roszik, Gregory Lizée, Cassian Yee	2017	24
8	Clinicopathological features and clinical outcomes associated with TP53 and BRAF^N^on‐^V⁶⁰⁰ mutations in cutaneous melanoma patients Cancer ·Dae Won Kim, Lauren E. Haydu, Aron Y. Joon, Roland L. Bassett, Alan Siroy, Michael T. Tetzlaff, Mark J. Routbort, Rodabe N. Amaria, Jennifer A. Wargo, Jennifer L. McQuade, Jennifer Needham, Patrick Hwu, Scott E. Woodman, Jason Roszik, Kevin B. Kim, Jeffrey E. Gershenwald, Alexander J. Lazar, Michael A. Davies	2016	34
9	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma Clinical Cancer Research ·Melissa Wilson, Fengmin Zhao, Sanika Khare, Jason Roszik, Scott E. Woodman, Kurt D’Andrea, Bradley Wubbenhorst, David L. Rimm, John M. Kirkwood, Harriet M. Kluger, Lynn M. Schuchter, Sandra J. Lee, Keith T. Flaherty, Katherine L. Nathanson	2015	31
10	Simultaneous Inhibition of the HGF/MET and Erk1/2 Pathways Affect Uveal Melanoma Cell Growth and Migration PLoS ONE ·Chandrani Chattopadhyay, Elizabeth A. Grimm, Scott E. Woodman	2014	1
11	HotSpotter: efficient visualization of driver mutations BMC Genomics ·Jason Roszik, Scott E. Woodman	2014	7
12	Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas Clinical Cancer Research ·Klaus Griewank, Henrike Westekemper, Rajmohan Murali, Nora R. Eibergen, Bastian Schilling, Thomas Wiesner, Tobias Schimming, Elisabeth Livingstone, Antje Sucker, Florian Grabellus, Claudia H.D. Metz, Daniela Süßkind, Uwe Hillen, Michael R. Speicher, Scott E. Woodman, Sreeranjini Prabhakaran, Dirk Schadendorf	2013	159
13	Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11 -Dependent Manner Clinical Cancer Research ·Jahan S. Khalili, Xiaoxing Yu, Ji Wang, Kristýna Weberová, Michael A. Davies, Gregory Lizée, Bita Esmaeli, Scott E. Woodman	2012	112
14	Targeting IGF-1R In Uveal Melanoma Cells Investigative Ophthalmology & Visual Science ·Chandrani Chattopadhyay, Scott E. Woodman, Bita Esmaeli, Elizabeth A. Grimm	2012	1
15	Profile of ipilimumab and its role in the treatment of metastatic melanoma Drug Design Development and Therapy ·Scott E. Woodman, Gargi Patel	2011	33
16	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf- Mutant Human Cutaneous Melanoma Cells Cancer Research ·Y.N. Vashisht Gopal, Wanleng Deng, Scott E. Woodman, Kakajan Komurov, Prahlad T. Ram, Paul D. Smith, Michael A. Davies	2010	177
17	Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates Molecular Cancer Therapeutics ·Scott E. Woodman, Jonathan C. Trent, Katherine Stemke‐Hale, Alexander J. Lazar, Sabrina Pricl, Giovanni M. Pavan, Maurizio Fermeglia, Y.N. Vashisht Gopal, Dan Yang, Donald A. Podoloff, Doina Ivan, Kevin B. Kim, Nikolaos G. Papadopoulos, Patrick Hwu, Gordon B. Mills, Michael A. Davies	2009	141
18	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma Clinical Cancer Research ·Michael A. Davies, Katherine Stemke‐Hale, E. Lin, Carmen S. Tellez, Wanleng Deng, Y.N. Vashisht Gopal, Scott E. Woodman, Tiffany L. Calderone, Zhenlin Ju, Alexander J. Lazar, Víctor G. Prieto, Kenneth Aldape, Gordon B. Mills, Jeffrey E. Gershenwald	2009	159
19	Proteasome Inhibitor (MG-132) Treatment of mdx Mice Rescues the Expression and Membrane Localization of Dystrophin and Dystrophin-Associated Proteins American Journal Of Pathology ·Gloria Bonuccelli, Federica Sotgia, William Schubert, David Park, Philippe G. Frank, Scott E. Woodman, Luigi Insabato, Michael Cammer, Carlo Minetti, Michael P. Lisanti	2003	110
20	Caveolin-1/3 Double-Knockout Mice Are Viable, but Lack Both Muscle and Non-Muscle Caveolae, and Develop a Severe Cardiomyopathic Phenotype American Journal Of Pathology ·David Park, Scott E. Woodman, William Schubert, Alex W. Cohen, Philippe G. Frank, Madhulika Chandra, Jamshid Shirani, Babak Razani, Baiyu Tang, Linda A. Jelicks, Stephen M. Factor, Louis M. Weiss, Herbert B. Tanowitz, Michael P. Lisanti	2002	170

About Scott E. Woodman

Scott E. Woodman is a scholar working on Oncology, Ophthalmology, Cancer Research, Cell Biology and Immunology, having authored 96 papers that have together received 6.1k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (21 papers), Cutaneous Melanoma Detection and Management (20 papers), Cancer Immunotherapy and Biomarkers (19 papers), Immunotherapy and Immune Responses (15 papers), CAR-T cell therapy research (15 papers), Caveolin-1 and cellular processes (14 papers), Cancer Genomics and Diagnostics (12 papers) and Ocular Oncology and Treatments (11 papers). The work is most often cited by research in Cell Biology (2.0k citations), Oncology (2.1k citations), Ophthalmology (624 citations), Immunology (1.3k citations) and Molecular Biology (3.3k citations). Scott E. Woodman has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Michael P. Lisanti, Babak Razani, Michael A. Davies, Philippe G. Frank, David Park, Jennifer A. Wargo, William Schubert, Jason Roszik, Chantale Bernatchez and Patrick Hwu. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, American Journal Of Pathology, Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact